Oral Antihyperglycemic Treatment Options for Type 2 Diabetes Mellitus

  • Brietzke S
  • 4


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


The epidemic of type 2 diabetes mellitus has been met by evolving strategy and clinical tactics, including the generally-accepted recommendation to initiate drug therapy concurrent with therapeutic lifestyle changes. Barring contraindications, metformin should be the first drug treatment prescribed, based on considerations of cost, efficacy, and safety. When metformin monotherapy fails to produce the goal for glycemic control, add-on therapy can include a sulfonylurea, a sodium-glucose transporter type 2 inhibitor, an alpha-glucosidase inhibitor, or a thiazolidinedione. New niche therapies include colesevelam and bromocriptine mesylate. Consideration should be given to the effect of the drug therapy on cardiovascular disease.

Author-supplied keywords

  • 2,4 thiazolidinedione derivative/dt [Drug Therapy]
  • 2,4 thiazolidinedione derivative/po [Oral Drug Adm
  • Bromocriptine
  • Colesevelam
  • Metformin
  • Sodium-glucose transporter-2 inhibitors (SGLT2 inh
  • Sulfonylureas
  • Thiazolidinediones
  • Type 2 diabetes mellitus
  • bromocriptine/dt [Drug Therapy]
  • bromocriptine/po [Oral Drug Administration]
  • cardiovascular disease
  • cardiovascular risk
  • clinical trial
  • colesevelam/dt [Drug Therapy]
  • colesevelam/po [Oral Drug Administration]
  • diarrhea/si [Side Effect]
  • drug dose reduction
  • drug efficacy
  • drug megadose
  • glibenclamide/ct [Clinical Trial]
  • glibenclamide/dt [Drug Therapy]
  • glibenclamide/po [Oral Drug Administration]
  • glimepiride/dt [Drug Therapy]
  • glimepiride/po [Oral Drug Administration]
  • health hazard
  • human
  • low drug dose
  • metformin/ae [Adverse Drug Reaction]
  • metformin/cm [Drug Comparison]
  • metformin/ct [Clinical Trial]
  • metformin/dt [Drug Therapy]
  • metformin/po [Oral Drug Administration]
  • nateglinide/ct [Clinical Trial]
  • nateglinide/dt [Drug Therapy]
  • nateglinide/po [Oral Drug Administration]
  • nausea/si [Side Effect]
  • non insulin dependent diabetes mellitus/dt [Drug T
  • oral antidiabetic agent/dt [Drug Therapy]
  • oral antidiabetic agent/po [Oral Drug Administrati
  • pioglitazone/cm [Drug Comparison]
  • pioglitazone/ct [Clinical Trial]
  • pioglitazone/dt [Drug Therapy]
  • placebo
  • repaglinide/ct [Clinical Trial]
  • repaglinide/dt [Drug Therapy]
  • repaglinide/po [Oral Drug Administration]
  • review
  • rosiglitazone/cm [Drug Comparison]
  • rosiglitazone/ct [Clinical Trial]
  • rosiglitazone/dt [Drug Therapy]
  • rosiglitazone/po [Oral Drug Administration]
  • sulfonylurea/dt [Drug Therapy]
  • sulfonylurea/po [Oral Drug Administration]

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • S A Brietzke

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free